Vancouver, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) today announced the voting results from its Annual General Meeting held on Sept. 21, 2017 in Vancouver, British Columbia. The total number of shares represented in person or by proxy at the...
Tailwinds' Take: Nice to see this patent as it shows they continue to make progress behind the scenes, despite their noticeable lack of marketing around the company and its shares.  Guilford, CT. Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or...
This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least, that's what has traditionally happened. There always remains the risk of finding your stockings filled...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because of it?), led by a 22% gain in Provention Bio, we managed to put up...
I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a swoon. This time, thanks to the ratcheting up of trade tension, we looked ready for...
Tailwinds' Take: Bioasis appears to have done the necessary pre-clinical work to attract interest from partners. While still early stage, it's apparent that the platform has significant promise and I expect to see more deals in the near future. GUILFORD,...
When I removed Bioasis from the Tailwinds Select Portfolio, it was with great reluctance. This is a Company that I believe has groundbreaking, lifesaving, technology. The management team is strong and the board is outstanding. All the pieces were...
Tailwinds' Take: needed financing to keep things going until they can land a strategic investor. The clock is ticking on my ability to hold this any longer. I'm expecting a bounce in early 2020 and, if they don't close...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) and the treatment of central nervous system (“CNS”) disorders in areas...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM  platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.